prevention of post-ERCP pancreatitis by placement of 4Fr prophylactic pancreatic duct stent

Phase 2

• Conditions: biliary duct disease

• Registration Number: JPRN-jRCTs052180132
• Lead Sponsor: Kitano Masayuki

Brief Summary

We could not clarify the effectiveness of 4Fr prophylactic pancreatic stent, because enrolled patient was only one.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-18
• Study Completion: 2019-06-05
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

1)native papilla
2)patient who is performed endoscopic retrograde cholangiography purposes only in the biliary duct

Exclusion Criteria

1)acute pancreatitis
2)postoperative reconstructed intestinal tract (Billroth ii, Roux-en-Y method)
3)patient with serious systemic illness, dangerous condition of life
4)intraductal papillary mucinous neoplasm
5)complete obstruction of main pancreatic duct
6)patient who already registered in this study once

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of post-endoscopic retrograde cholangiopancreatography pancreatitis

Secondary Outcome Measures

Name	Time	Method
Success rate of placing prophylactic pancreatic duct stent.<br>Frequency of more than moderate post-endoscopic retrograde cholangiopancreatography pancreatitis.<br>Frequency of complication other than post-endoscopic retrograde cholangiopancreatography pancreatitis.